Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inhix
- Development stage
- Unknown
- Lead developer
- Gerresheimer
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Inhix is a dry powder inhaler combining fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting beta-2 adrenergic agonist. Developed by Vectura Group plc, this combination drug is designed for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It works by reducing inflammation in the airways and providing bronchodilation to improve lung function. The drug is delivered using Vectura's proprietary Osmohale and Fulflo platforms.
- Brand names
- Inhix
- Other names
- fluticasone furoate/vilanterolfluticasone furoate/vilanterol dry powder inhaler
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Inhix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhix.